{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-001831","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.500588+00:00","generated_at":"2026-06-20T00:03:24.685847+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Clearside Biomedical CMO/CVO Thomas Ciulla resigns effective Feb 17; will serve as advisor","bullets":["Thomas Ciulla resigns as Chief Medical Officer and Chief Development Officer of Clearside Biomedical.","Resignation effective February 17, 2023; he will continue as Chairman of Scientific Advisory Board.","Ciulla will also serve as Chief Medical Advisor – Retina under a proposed consulting agreement.","No successor named; Ciulla’s advisory role aims to maintain continuity in clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-001831","json":"https://secwatch.observer/filing/0000950170-23-001831.json","markdown":"https://secwatch.observer/filing/0000950170-23-001831.md","text":"https://secwatch.observer/filing/0000950170-23-001831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023001831/0000950170-23-001831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023001831/clsd-20230202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T00:03:24.685847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95966b3d75","claim":"Thomas Ciulla resigned as Chief Medical Officer and Chief Development Officer at Clearside Biomedical, Inc..","evidence_excerpt":"On February 2, 2023, Thomas Ciulla provided Clearside Biomedical, Inc. (the “ Company ”) notice of his resignation from his position as Chief Medical Officer and Chief Development Officer of the Company, with such resignation to be effective on February 17. 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023001831/0000950170-23-001831-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer and Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}